Drug Trial Radar · NCT05735080
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Mar 28, 2023
Primary completion
Jul 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Incyclix BioIndustry
- Sponsor type
- Industry
- First posted
- Feb 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 in patients with recurrent advanced/metastatic cancer, including hormone receptor positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) regimen, and CCNE1-amplified solid tumors who progressed on standard of care treatment. The study will be conducted in 3 parts: Part A (INX-315 monotherapy dose escalation and combination therapy with fulvestrant), Part B (ovarian cancer INX-315 monotherapy dose expansion), and Part C (INX-315 combination therapy with abemaciclib \[a CDK4/6i\] and fulvestrant \[a SERD\] in advanced/metastatic breast cancer; dose escalation and expansion).
Conditions
- Breast Cancer
- Breast Cancer Metastatic
- Hormone Receptor Positive Tumor
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Ovarian Cancer
- CCNE1 Amplification
- Solid Tumor
- Advanced Cancer
- Metastatic Cancer
Interventions
INX-315Drug
Oral administration
FulvestrantDrug
Fulvestrant will be combined with INX-315
AbemaciclibDrug
Abemaciclib will be combined with INX-315
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A and B: Evaluate the incidents of treatment emergent adverse events and laboratory abnormalities in INX-315 monotherapy and in combination with fulvestrantTime frame: Up to 12 months
- Part A: Evaluate the occurrence of dose-limiting toxicities (DLTs) during Cycle 1Time frame: 28 days
- Part A: Recommend at least two doses of INX-315 to be evaluated in the expansion phaseTime frame: Up to 12 months
- Part B: Overall response rate (ORR)Time frame: Up to 36 months
- Part B: Selection of Recommended Phase 2 Dose (RP2D)Time frame: Up to 36 months
- Part C Evaluate the incidents of treatment emergent adverse events and laboratory abnormalities for patients in combination treatment (INX_315+abemaciclib+fulvestrant)Time frame: Up to 12 months
- Part C - Evaluate the antitumor activity of INX-315 in combination with abemaciclib and fulvestrantTime frame: Up to 12 months
Locations
18 sites in 2 countries. Site status is shown where the registry gives one.
Florida Cancer Specialists
Orlando, Florida · Recruiting
Emory Winship Cancer Institute
Atlanta, Georgia · Recruiting
Georgia Cancer Center at Augusta University
Augusta, Georgia · Recruiting
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Roswell Park Cancer Institute
Buffalo, New York · Recruiting
Levine Cancer Institute (LCI)- Atrium Health
Charlotte, North Carolina · Recruiting
Duke Cancer Center/ DUMC
Durham, North Carolina · Recruiting
Gabrail Cancer Research Center
Canton, Ohio · Recruiting
Next Oncology
Dallas, Texas · Recruiting
UTSW Medical Center
Dallas, Texas · Recruiting
Oncology Consultants
Houston, Texas · Not yet recruiting
Next Oncology
Houston, Texas · Recruiting
Northwest Medical Specialties, PLLC
Tacoma, Washington · Recruiting
Mater Hospital
South Brisbane, Australia · Recruiting
Peninsula and South Eastern Haematology & Oncology Group
Frankston, Victoria, Australia · Recruiting
Peter MacCallum Cancer Center
Parkville, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.